- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05600777
En 24-ugers undersøgelse af effektiviteten og sikkerheden af BLU-5937 hos voksne med refraktær kronisk hoste (CALM-2) (CALM-2)
Et fase 3, 24-ugers, randomiseret, dobbeltblindt, placebokontrolleret, parallelarms effektivitet og sikkerhedsundersøgelse med Open-Label forlængelse af BLU-5937 hos voksne deltagere med refraktær kronisk hoste, inklusive uforklarlig kronisk hoste
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The primary efficacy objective is to assess the effect of BLU-5937 on 24-hour cough frequency in adults with refractory chronic cough (including unexplained chronic cough) at 24 weeks.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
New South Wales
-
Coffs Harbour, New South Wales, Australien, 2450
- GSK Investigational Site
-
Macquarie University, New South Wales, Australien, 2109
- GSK Investigational Site
-
New Lambton, New South Wales, Australien, 2305
- GSK Investigational Site
-
St Leonards, New South Wales, Australien, 2065
- GSK Investigational Site
-
-
Queensland
-
Chermside, Queensland, Australien, 4032
- GSK Investigational Site
-
-
South Australia
-
Adelaide, South Australia, Australien, 5000
- GSK Investigational Site
-
-
Victoria
-
St Albans, Victoria, Australien, 3021
- GSK Investigational Site
-
-
Western Australia
-
Nedlands, Western Australia, Australien, 6009
- GSK Investigational Site
-
Spearwood, Western Australia, Australien, 6163
- GSK Investigational Site
-
-
-
-
-
Burlington, Canada, ON L7N 3V2
- GSK Investigational Site
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 1N4
- GSK Investigational Site
-
-
Ontario
-
Ajax, Ontario, Canada, L1S 2J5
- GSK Investigational Site
-
Hamilton, Ontario, Canada, L8N 3Z5
- GSK Investigational Site
-
Hamilton, Ontario, Canada, L8L 5G4
- GSK Investigational Site
-
Toronto, Ontario, Canada, M5T 3A9
- GSK Investigational Site
-
Windsor, Ontario, Canada, N8X 1T3
- GSK Investigational Site
-
-
Quebec
-
Montreal, Quebec, Canada, H1Y3H5
- GSK Investigational Site
-
Québec, Quebec, Canada, G1V 4W2
- GSK Investigational Site
-
Québec, Quebec, Canada, G1V 4T3
- GSK Investigational Site
-
Saint-Charles-Borromée, Quebec, Canada, J6E 2B4
- GSK Investigational Site
-
Trois-Rivières, Quebec, Canada, G8T 7A1
- GSK Investigational Site
-
Victoriaville, Quebec, Canada, G6P 3Z8
- GSK Investigational Site
-
-
-
-
-
Belfast, Det Forenede Kongerige, BT7 2EB
- GSK Investigational Site
-
Bristol, Det Forenede Kongerige, BS374AX
- GSK Investigational Site
-
Chelmsford, Det Forenede Kongerige, CM1 7ET
- GSK Investigational Site
-
Corby, Det Forenede Kongerige, NN17 2UR
- GSK Investigational Site
-
Corby, Det Forenede Kongerige, NN18 9EZ
- GSK Investigational Site
-
Coventry, Det Forenede Kongerige, CV3 4FJ
- GSK Investigational Site
-
Hayle, Det Forenede Kongerige, TR27 5DT
- GSK Investigational Site
-
Hull, Det Forenede Kongerige, HU16 5JQ
- GSK Investigational Site
-
London, Det Forenede Kongerige, SE5 9RS
- GSK Investigational Site
-
Orpington, Det Forenede Kongerige, BR5 3QG
- GSK Investigational Site
-
Peterborough, Det Forenede Kongerige, PE3 9GZ
- GSK Investigational Site
-
Preston, Det Forenede Kongerige, PR2 9HT
- GSK Investigational Site
-
Shipley, Det Forenede Kongerige, BD18 3SA
- GSK Investigational Site
-
Tyne and Wear, Det Forenede Kongerige, NE29 8NH
- GSK Investigational Site
-
Wishaw, Det Forenede Kongerige, ML2 0DP
- GSK Investigational Site
-
-
Middlesex
-
Northwood, Middlesex, Det Forenede Kongerige, HA6 2RN
- GSK Investigational Site
-
-
West Yorkshire
-
Bradford, West Yorkshire, Det Forenede Kongerige, BD9 6RJ
- GSK Investigational Site
-
-
-
-
Alabama
-
Foley, Alabama, Forenede Stater, 36535
- GSK Investigational Site
-
-
Arizona
-
Litchfield Park, Arizona, Forenede Stater, 85340
- GSK Investigational Site
-
Phoenix, Arizona, Forenede Stater, 85032
- GSK Investigational Site
-
-
California
-
Los Angeles, California, Forenede Stater, 90025
- GSK Investigational Site
-
Los Angeles, California, Forenede Stater, 90048
- GSK Investigational Site
-
Paramount, California, Forenede Stater, 90723-5433
- GSK Investigational Site
-
Sacramento, California, Forenede Stater, 95661
- GSK Investigational Site
-
San Diego, California, Forenede Stater, 92120
- GSK Investigational Site
-
San Diego, California, Forenede Stater, 92108
- GSK Investigational Site
-
San Jose, California, Forenede Stater, 95117
- GSK Investigational Site
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80012
- GSK Investigational Site
-
Colorado Springs, Colorado, Forenede Stater, 80923
- GSK Investigational Site
-
Denver, Colorado, Forenede Stater, 80230-6406
- GSK Investigational Site
-
Wheat Ridge, Colorado, Forenede Stater, 96001
- GSK Investigational Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20007
- GSK Investigational Site
-
-
Florida
-
Daytona Beach, Florida, Forenede Stater, 32117
- GSK Investigational Site
-
DeBary, Florida, Forenede Stater, 32713-2260
- GSK Investigational Site
-
Fort Lauderdale, Florida, Forenede Stater, 33324
- GSK Investigational Site
-
Jacksonville, Florida, Forenede Stater, 32224
- GSK Investigational Site
-
Leesburg, Florida, Forenede Stater, 34748
- GSK Investigational Site
-
Santa Rosa Beach, Florida, Forenede Stater, 32459
- GSK Investigational Site
-
Sarasota, Florida, Forenede Stater, 34239
- GSK Investigational Site
-
Sweetwater, Florida, Forenede Stater, 33172-2732
- GSK Investigational Site
-
-
Georgia
-
Cumming, Georgia, Forenede Stater, 30041-7536
- GSK Investigational Site
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60612
- GSK Investigational Site
-
River Forest, Illinois, Forenede Stater, 60305
- GSK Investigational Site
-
-
Iowa
-
West Des Moines, Iowa, Forenede Stater, 50266-8216
- GSK Investigational Site
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 40509-1801
- GSK Investigational Site
-
-
Maryland
-
Chevy Chase, Maryland, Forenede Stater, 20815
- GSK Investigational Site
-
-
Massachusetts
-
Methuen, Massachusetts, Forenede Stater, 01844
- GSK Investigational Site
-
North Dartmouth, Massachusetts, Forenede Stater, 02747
- GSK Investigational Site
-
-
Michigan
-
Ypsilanti, Michigan, Forenede Stater, 48197
- GSK Investigational Site
-
-
Minnesota
-
Edina, Minnesota, Forenede Stater, 55435
- GSK Investigational Site
-
Rochester, Minnesota, Forenede Stater, 55905-0001
- GSK Investigational Site
-
Woodbury, Minnesota, Forenede Stater, 55125
- GSK Investigational Site
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63141
- GSK Investigational Site
-
St Louis, Missouri, Forenede Stater, 63141-6282
- GSK Investigational Site
-
-
Montana
-
Missoula, Montana, Forenede Stater, 59808
- GSK Investigational Site
-
-
Nebraska
-
Lincoln, Nebraska, Forenede Stater, 68516
- GSK Investigational Site
-
Omaha, Nebraska, Forenede Stater, 68124
- GSK Investigational Site
-
-
North Carolina
-
Charlotte, North Carolina, Forenede Stater, 28211
- GSK Investigational Site
-
Gastonia, North Carolina, Forenede Stater, 28054-7481
- GSK Investigational Site
-
Winston-Salem, North Carolina, Forenede Stater, 27103-3921
- GSK Investigational Site
-
-
Ohio
-
Columbus, Ohio, Forenede Stater, 43235
- GSK Investigational Site
-
-
Oklahoma
-
Tulsa, Oklahoma, Forenede Stater, 74136
- GSK Investigational Site
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97213
- GSK Investigational Site
-
-
Pennsylvania
-
Danville, Pennsylvania, Forenede Stater, 17822-9800
- GSK Investigational Site
-
Philadelphia, Pennsylvania, Forenede Stater, 19107
- GSK Investigational Site
-
-
Rhode Island
-
Warwick, Rhode Island, Forenede Stater, 02886
- GSK Investigational Site
-
-
South Carolina
-
Anderson, South Carolina, Forenede Stater, 29621
- GSK Investigational Site
-
Charleston, South Carolina, Forenede Stater, 29412
- GSK Investigational Site
-
Charleston, South Carolina, Forenede Stater, 29406
- GSK Investigational Site
-
Gaffney, South Carolina, Forenede Stater, 29340-4737
- GSK Investigational Site
-
-
Tennessee
-
Franklin, Tennessee, Forenede Stater, 37067
- GSK Investigational Site
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75231-4307
- GSK Investigational Site
-
Round Rock, Texas, Forenede Stater, 78681
- GSK Investigational Site
-
San Antonio, Texas, Forenede Stater, 78258
- GSK Investigational Site
-
-
Virginia
-
Norfolk, Virginia, Forenede Stater, 23507
- GSK Investigational Site
-
-
Washington
-
Bellingham, Washington, Forenede Stater, 98225
- GSK Investigational Site
-
-
-
-
-
Faridabad, Indien, 121006
- GSK Investigational Site
-
Nagpur, Indien, 44009
- GSK Investigational Site
-
Nashik, Indien, 422001
- GSK Investigational Site
-
Visakhapatnam, Indien, 530017
- GSK Investigational Site
-
-
-
-
-
Aichi, Japan, 467-8602
- GSK Investigational Site
-
Akita, Japan, 010-8543
- GSK Investigational Site
-
Chiba, Japan, 260-8677
- GSK Investigational Site
-
Fukui, Japan, 910-1193
- GSK Investigational Site
-
Fukuoka, Japan, 812-8582
- GSK Investigational Site
-
Fukuoka, Japan, 819-8555
- GSK Investigational Site
-
Fukuoka, Japan, 807-8556
- GSK Investigational Site
-
Fukushima, Japan, 960-1295
- GSK Investigational Site
-
Gifu, Japan, 509-6134
- GSK Investigational Site
-
Gifu, Japan, 501-6062
- GSK Investigational Site
-
Gifu, Japan, 153-8515
- GSK Investigational Site
-
Hiroshima, Japan, 735-8585
- GSK Investigational Site
-
Hokkaido, Japan, 064-0804
- GSK Investigational Site
-
Hyōgo, Japan, 670-8520
- GSK Investigational Site
-
Hyōgo, Japan, 663-8501
- GSK Investigational Site
-
Hyōgo, Japan, 672-8064
- GSK Investigational Site
-
Hyōgo, Japan, 674-0063
- GSK Investigational Site
-
Ibaraki, Japan, 319-1113
- GSK Investigational Site
-
Kagawa, Japan, 761-8073
- GSK Investigational Site
-
Kagoshima, Japan, 890-8520
- GSK Investigational Site
-
Kanagawa, Japan, 232-0024
- GSK Investigational Site
-
Kanagawa, Japan, 234-8503
- GSK Investigational Site
-
Kanagawa, Japan, 231-8682
- GSK Investigational Site
-
Kyoto, Japan, 606-8507
- GSK Investigational Site
-
Kyoto, Japan, 612-8555
- GSK Investigational Site
-
Mie, Japan, 515-8544
- GSK Investigational Site
-
Miyazaki, Japan, 889-4304
- GSK Investigational Site
-
Nagasaki, Japan, 852-8501
- GSK Investigational Site
-
Nankoku-shi, Japan, 783-8509
- GSK Investigational Site
-
Niigata, Japan, 950-1197
- GSK Investigational Site
-
Osaka, Japan, 545-8586
- GSK Investigational Site
-
Osaka, Japan, 589-8511
- GSK Investigational Site
-
Osaka, Japan, 591-8555
- GSK Investigational Site
-
Osaka, Japan, 577-0843
- GSK Investigational Site
-
Saitama, Japan, 350-0495
- GSK Investigational Site
-
Shizuoka, Japan, 420-8527
- GSK Investigational Site
-
Shizuoka, Japan, 432-8002
- GSK Investigational Site
-
Shizuoka, Japan, 426-8677
- GSK Investigational Site
-
Shizuoka, Japan, 433-8558
- GSK Investigational Site
-
Tochigi, Japan, 321-0293
- GSK Investigational Site
-
Tokyo, Japan, 150-8935
- GSK Investigational Site
-
Tokyo, Japan, 104-0031
- GSK Investigational Site
-
Tokyo, Japan, 173-8606
- GSK Investigational Site
-
Tokyo, Japan, 204-8522
- GSK Investigational Site
-
Tokyo, Japan, 140-8522
- GSK Investigational Site
-
Yokohama, Japan, 236-0004
- GSK Investigational Site
-
-
-
-
-
Changsha, Kina, 410008
- GSK Investigational Site
-
Chengdu, Kina, 610041
- GSK Investigational Site
-
Chongqing, Kina, 408099
- GSK Investigational Site
-
Dongguan, Kina, 523326
- GSK Investigational Site
-
Ganzhou, Kina, 341000
- GSK Investigational Site
-
Guangzhou, Kina, 510000
- GSK Investigational Site
-
Hangzhou, Kina, 310003
- GSK Investigational Site
-
Hefei, Kina, 230001
- GSK Investigational Site
-
Hefei, Kina, 230022
- GSK Investigational Site
-
Hohhot, Kina, 010017
- GSK Investigational Site
-
Huizhou, Kina, 516001
- GSK Investigational Site
-
Huizhou, Kina, 516000
- GSK Investigational Site
-
Jiangsu, Kina, 221004
- GSK Investigational Site
-
Jinan, Kina, 250021
- GSK Investigational Site
-
Jingzhou, Kina, 434020
- GSK Investigational Site
-
Kunming, Kina, 650032
- GSK Investigational Site
-
Liuzhou, Kina
- GSK Investigational Site
-
Meizhou, Kina, 514700
- GSK Investigational Site
-
Nanchang, Kina, 330038
- GSK Investigational Site
-
Pingxiang, Kina, 337055
- GSK Investigational Site
-
Shanghai, Kina, 200032
- GSK Investigational Site
-
Shanghai, Kina, 200065
- GSK Investigational Site
-
Shanghai, Kina, 200080
- GSK Investigational Site
-
Shenyang, Kina, 110004
- GSK Investigational Site
-
Shenzhen, Kina, 518053
- GSK Investigational Site
-
Taizhou, Kina, 317000
- GSK Investigational Site
-
Wenzhou, Kina, 325000
- GSK Investigational Site
-
Xiamen, Kina, 361004
- GSK Investigational Site
-
Yangzhou, Kina, 225001
- GSK Investigational Site
-
Yinchuan, Kina
- GSK Investigational Site
-
Zhanjiang, Kina, 524045
- GSK Investigational Site
-
-
Xinjiang
-
Ürümqi, Xinjiang, Kina, 830001
- GSK Investigational Site
-
-
-
-
-
Auckland, New Zealand, 0626
- GSK Investigational Site
-
Christchurch, New Zealand, 8011
- GSK Investigational Site
-
Christchurch, New Zealand, 8013
- GSK Investigational Site
-
Dunedin, New Zealand, 9016
- GSK Investigational Site
-
Hamilton, New Zealand, 3200
- GSK Investigational Site
-
Kapiti, New Zealand, 5036
- GSK Investigational Site
-
Nelson, New Zealand, 7011
- GSK Investigational Site
-
New Lynn, New Zealand, 0600
- GSK Investigational Site
-
Rotorua, New Zealand, 3010
- GSK Investigational Site
-
Tauranga, New Zealand, 3110
- GSK Investigational Site
-
-
Hawke's Bay Region
-
Havelock North, Hawke's Bay Region, New Zealand, 3410
- GSK Investigational Site
-
-
Upper Hutt
-
Ebdentown, Upper Hutt, New Zealand, 5018
- GSK Investigational Site
-
-
-
-
-
Bardejov, Slovakiet, 08501
- GSK Investigational Site
-
Bardejov, Slovakiet, 8501
- GSK Investigational Site
-
Humenné, Slovakiet, 06601
- GSK Investigational Site
-
Kežmarok, Slovakiet, 060 01
- GSK Investigational Site
-
Košice, Slovakiet, 040 01
- GSK Investigational Site
-
Prievidza, Slovakiet, 97101
- GSK Investigational Site
-
Spišská Nová Ves, Slovakiet, 052 01
- GSK Investigational Site
-
-
-
-
-
Incheon, Sydkorea, 21431
- GSK Investigational Site
-
Jeonju, Sydkorea, 54907
- GSK Investigational Site
-
Pusan, Sydkorea, 49241
- GSK Investigational Site
-
Seongnam, Sydkorea, 13620
- GSK Investigational Site
-
Seoul, Sydkorea, 03080
- GSK Investigational Site
-
Seoul, Sydkorea, 06591
- GSK Investigational Site
-
Seoul, Sydkorea, 03312
- GSK Investigational Site
-
Seoul, Sydkorea, 08308
- GSK Investigational Site
-
Seoul, Sydkorea, 03722
- GSK Investigational Site
-
Seoul, Sydkorea, 5030
- GSK Investigational Site
-
Seoul, Sydkorea, 5505
- GSK Investigational Site
-
Seoul, Sydkorea, 6351
- GSK Investigational Site
-
Wŏnju, Sydkorea, 26426
- GSK Investigational Site
-
-
-
-
-
Changhua, Taiwan, 50006
- GSK Investigational Site
-
Kaohsiung City, Taiwan, 807
- GSK Investigational Site
-
Kaohsiung City, Taiwan, 82445
- GSK Investigational Site
-
Taoyuan, Taiwan, 333
- GSK Investigational Site
-
-
-
-
-
Brandýs nad Labem, Tjekkiet, 25001
- GSK Investigational Site
-
Brno, Tjekkiet, 62500
- GSK Investigational Site
-
Kralupy nad Vltavou, Tjekkiet, 278 01
- GSK Investigational Site
-
Miroslav, Tjekkiet, 671 72
- GSK Investigational Site
-
Olomouc, Tjekkiet, 77900
- GSK Investigational Site
-
Prague, Tjekkiet, 14800
- GSK Investigational Site
-
Strakonice, Tjekkiet, 38601
- GSK Investigational Site
-
-
-
-
-
Berlin, Tyskland, 10117
- GSK Investigational Site
-
Berlin, Tyskland, 10969
- GSK Investigational Site
-
Bochum, Tyskland, 44787
- GSK Investigational Site
-
Dresden, Tyskland, 01069
- GSK Investigational Site
-
Essen, Tyskland, 45355
- GSK Investigational Site
-
Frankfurt, Tyskland, 60596
- GSK Investigational Site
-
Frankfurt am Main, Tyskland, 60315
- GSK Investigational Site
-
Hamburg, Tyskland, 20253
- GSK Investigational Site
-
Lübeck, Tyskland, 23552
- GSK Investigational Site
-
Marburg, Tyskland, 35037
- GSK Investigational Site
-
München, Tyskland, 81241
- GSK Investigational Site
-
-
Baden-Wurttemberg
-
Heidelberg, Baden-Wurttemberg, Tyskland, 69126
- GSK Investigational Site
-
Karlsruhe, Baden-Wurttemberg, Tyskland, 76137
- GSK Investigational Site
-
-
Hesse
-
Darmstadt, Hesse, Tyskland, 64283
- GSK Investigational Site
-
Frankfurt am Main, Hesse, Tyskland, 60590
- GSK Investigational Site
-
Frankfurt am Main, Hesse, Tyskland, 60596
- GSK Investigational Site
-
Neu-Isenburg, Hesse, Tyskland, 63263
- GSK Investigational Site
-
-
Lower Saxony
-
Hanover, Lower Saxony, Tyskland, 30159
- GSK Investigational Site
-
Hanover, Lower Saxony, Tyskland, 30173
- GSK Investigational Site
-
Peine, Lower Saxony, Tyskland, 31224
- GSK Investigational Site
-
-
Saxony-Anhalt
-
Halle, Saxony-Anhalt, Tyskland, 06108
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Geesthacht, Schleswig-Holstein, Tyskland, 21502
- GSK Investigational Site
-
Schleswig, Schleswig-Holstein, Tyskland, 24837
- GSK Investigational Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Capable of giving signed informed consent
- Refractory chronic cough (including unexplained chronic cough) for at least one year
- Women of child-bearing potential must use a highly effective contraception method during the study and for at least 14 days after the last dose
Exclusion Criteria:
- Current smoker/vaper (all forms of smoking and inhaled substances, including, cannabis/tobacco smoke and nicotine vapors) or individuals who have given up smoking within the past 6 months, or those with >20 pack-year smoking history
- Diagnosis of chronic obstructive pulmonary disease, bronchiectasis, chronic bronchitis, cystic fibrosis, pulmonary sarcoidosis, idiopathic pulmonary fibrosis, uncontrolled asthma, or other significant or progressive airway/respiratory disorder that might affect cough based on clinician assessment
- Respiratory tract infection within 4 weeks before screening
- Laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection at screening
- History of malignancy in the last 5 years
- History of alcohol or drug abuse within the last 3 years
- Has a positive serologic test for human immunodeficiency virus (HIV), hepatitis B virus surface antigen, or hepatitis C virus.
- Previous participation in a BLU-5937 trial
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: BLU-5937 25 mg
BLU-5937 oral dose 25 mg twice a day. |
Oral administration of BLU-5937 Tablets
Andre navne:
|
|
Eksperimentel: BLU-5937 50 mg
BLU-5937 oral dose 50 mg twice a day. |
Oral administration of BLU-5937 Tablets
Andre navne:
|
|
Placebo komparator: Placebo
Matching Placebo for BLU-5937 oral dose twice a day. |
Oral administration of matching placebo for BLU-5937 Tablets |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Ændring fra baseline i vitale tegn: systolisk og diastolisk blodtryk (millimeter kviksølv [mm Hg]) i uge 24
Tidsramme: Baseline, uge 24
|
Baseline, uge 24
|
|
|
Skift fra baseline i vital tegn: puls (beats pr. Minut) i uge 24
Tidsramme: Baseline, uge 24
|
Baseline, uge 24
|
|
|
Skift fra baseline i vital tegn: åndedrætsfrekvens (åndedræt pr. Minut) i uge 24
Tidsramme: Baseline, uge 24
|
Baseline, uge 24
|
|
|
Skift fra baseline i vital tegn: kropstemperatur (grader celsius) i uge 24
Tidsramme: Baseline, uge 24
|
Baseline, uge 24
|
|
|
Skift fra baseline i vital tegn: Vægt (kg [kg]) i uge 24
Tidsramme: Baseline, uge 24
|
Baseline, uge 24
|
|
|
Ændring fra baseline i mandlig reproduktiv hormon: total testosteron (nanomoler pr. Liter [nmol/l]) i uge 24
Tidsramme: Baseline, uge 24
|
Baseline, uge 24
|
|
|
Ændring fra baseline i mandlige reproduktive hormoner: follikelstimulerende hormon [FSH] og luteiniserende hormon [LH] (internationale enheder pr. Liter [IU/L]) i uge 24
Tidsramme: Baseline, uge 24
|
Baseline, uge 24
|
|
|
Ændring fra baseline i mandlig reproduktiv hormon: inhibin B (nanogrammer pr. Liter [ng/l]) i uge 24
Tidsramme: Baseline, uge 24
|
Baseline, uge 24
|
|
|
Ændring fra baseline i hæmatologi Parameter: Røde blodlegemer (RBC) tælling (10^12 celler pr. Liter) i uge 24
Tidsramme: Baseline, uge 24
|
Baseline, uge 24
|
|
|
Ændring fra baseline i hæmatologiparametre: hæmoglobin og gennemsnitlig corpuskulær hæmoglobinkoncentration (MCHC) (gram pr. Liter [g/l]) i uge 24
Tidsramme: Baseline, uge 24
|
Baseline, uge 24
|
|
|
Ændring fra baseline i hæmatologi Parameter: Hematocrit (procentdel) i uge 24
Tidsramme: Baseline, uge 24
|
Baseline, uge 24
|
|
|
Ændring fra baseline i hæmatologi Parameter: Gennemsnitlig corpuskulær volumen (MCV) (femtoliters [FL]) i uge 24
Tidsramme: Baseline, uge 24
|
Baseline, uge 24
|
|
|
Ændring fra baseline i hæmatologiparameter: gennemsnitlig corpuskulær hæmoglobin (MCH) (picograms pr. Celle [PG/celle]) i uge 24
Tidsramme: Baseline, uge 24
|
Baseline, uge 24
|
|
|
Ændring fra baseline i hæmatologi Parameter: Red Cell Distribution Bredde (RDW) (procentdel) i uge 24
Tidsramme: Baseline, uge 24
|
Baseline, uge 24
|
|
|
Ændring fra baseline i hæmatologiparametre: hvide blodlegemer (WBC) tælling (neutrofiler, lymfocytter, monocytter, eosinofiler og basofiler) og blodpladetælling (10^9 celler pr. Liter) i uge 24
Tidsramme: Baseline, uge 24
|
Baseline, uge 24
|
|
|
Ændring fra baseline i kliniske kemi-parametre: alaninaminotransferase (ALT), aspartataminotransferase (AST) og gamma-glutamyltransferase (GGT) (enheder pr. Liter [U/L]) i uge 24
Tidsramme: Baseline, uge 24
|
Baseline, uge 24
|
|
|
Ændring fra baseline i kliniske kemi -parametre: alkalisk phosphatase (ALP) og kreatinkinase (CK) (internationale enheder pr. Liter [IU/L]) i uge 24
Tidsramme: Baseline, uge 24
|
Baseline, uge 24
|
|
|
Ændring fra baseline i kliniske kemi -parametre: total bilirubin, direkte og indirekte bilirubin og kreatinin (mikromol pr. Liter) i uge 24
Tidsramme: Baseline, uge 24
|
Baseline, uge 24
|
|
|
Ændring fra baseline i kliniske kemi -parametre: natrium, kalium, chlorid, calcium, magnesium, bicarbonat, glukose og blodurinstofnitrogen (BUN) (millimoler pr. Liter [mmol/L]) i uge 24
Tidsramme: Baseline, uge 24
|
Baseline, uge 24
|
|
|
Ændring fra baseline i kliniske kemi -parametre: protein og albumin (gram pr. Liter [g/l]) i uge 24
Tidsramme: Baseline, uge 24
|
Baseline, uge 24
|
|
|
Ændring fra baseline i klinisk kemi Parameter: estimeret glomerulær filtreringshastighed (EGFR) (ml pr. Minut pr. 1,73 meter kvadrat [ml/min/1,73 m^2]) i uge 24
Tidsramme: Baseline, uge 24
|
Baseline, uge 24
|
|
|
Ændring fra baseline i kliniske kemi -parametre: Prothrombin Time (PT) og aktiveret delvis thromboplastin -tid (APTT) (sekunder) i uge 24
Tidsramme: Baseline, uge 24
|
Baseline, uge 24
|
|
|
Ændring fra baseline i elektrokardiogram (EKG) værdi: hjerterytme (beats pr. Minut) i uge 24
Tidsramme: Baseline, uge 24
|
Baseline, uge 24
|
|
|
Ændring fra baseline i EKG -værdi: PR -interval, QT -interval, RR -interval, QRS -interval og korrigeret QT -interval ved hjælp af Fridericias formel (QTCF) (millisekunder) i uge 24
Tidsramme: Baseline, uge 24
|
Baseline, uge 24
|
|
|
24-Hour Cough Frequency
Tidsramme: Week 24
|
Assessed using an ambulatory cough monitor |
Week 24
|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) up to Week 24
Tidsramme: Up to Week 24
|
An AE is any untoward medical occurrence in a clinical study participant administered a medicinal product and which does not necessarily have a causal relationship with that product. An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death, is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in the offspring of a study participant; or other situations as per the medical or scientific judgment of the Investigator. |
Up to Week 24
|
|
Number of Participants with Adverse Events of Medical Interest (AEMIs) up to Week 24
Tidsramme: Up to Week 24
|
An AEMI is an event of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring is appropriate. The following are AEMIs for this study: taste disturbance, oral hypoesthesia, oral paresthesia, and new or worsening findings of the cornea. |
Up to Week 24
|
|
Number of Participants with Study Treatment Discontinuation due to AEs and SAEs up to Week 24
Tidsramme: Up to Week 24
|
An AE is any untoward medical occurrence in a clinical study participant administered a medicinal product and which does not necessarily have a causal relationship with that product. An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death, is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in the offspring of a study participant; or other situations as per the medical or scientific judgment of the Investigator. |
Up to Week 24
|
|
Number of Participants with AEs and SAEs Leading to Study Withdrawal up to Week 24
Tidsramme: Up to Week 24
|
An AE is any untoward medical occurrence in a clinical study participant administered a medicinal product and which does not necessarily have a causal relationship with that product. An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death, is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in the offspring of a study participant; or other situations as per the medical or scientific judgment of the Investigator. |
Up to Week 24
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from Baseline in Cough Severity Visual Analogue Scale at Week 24
Tidsramme: Baseline, Week 24
|
Assessed by Cough Severity Visual Analogue Scale [VAS] by the participant on a 100 mm visual analogue scale where higher scores indicate greater severity. |
Baseline, Week 24
|
|
Percentage of Participants With Greater than or Equal to (>=) 30 mm Reduction From Baseline in Cough Severity Visual Analog Scale at Week 24
Tidsramme: Baseline, Week 24
|
Assessed by Cough Severity Visual Analogue Scale [VAS] by the participant on a 100 mm visual analogue scale where higher scores indicate greater severity. |
Baseline, Week 24
|
|
Awake Cough Frequency at Week 24
Tidsramme: Week 24
|
Assessed using an ambulatory cough monitor |
Week 24
|
|
Percentage of Participants With >= 30 percent (%) Reduction From Baseline in 24-Hour Cough Frequency at Week 24
Tidsramme: Baseline, Week 24
|
Assessed using an ambulatory cough monitor |
Baseline, Week 24
|
|
Change from Baseline in the Leicester Cough Questionnaire (LCQ) Total Score at Week 24
Tidsramme: Baseline, Week 24
|
The LCQ is a patient-reported quality of life (QOL) measure of chronic cough. The questionnaire consists of 19 items to which the patient responds on a 7-point Likert response scale (from 1 to 7). Each item assesses symptoms during cough and the impact of cough on 3 domains: physical, psychological, and social. Domain scores range from 1-7, and the total score ranges from 3 - 21; a higher score indicates a better quality of life. |
Baseline, Week 24
|
|
Percentage of Participants With a >= 1.3-point Increase From Baseline in Leicester Cough Questionnaire (LCQ) Total Score at Week 24
Tidsramme: Baseline, Week 24
|
The LCQ is a patient-reported quality of life (QOL) measure of chronic cough. The questionnaire consists of 19 items to which the patient responds on a 7-point Likert response scale (from 1 to 7). Each item assesses symptoms during cough and the impact of cough on 3 domains: physical, psychological, and social. Domain scores range from 1-7, and the total score ranges from 3 - 21; a higher score indicates a better quality of life. |
Baseline, Week 24
|
|
Change from Baseline in the Chronic Cough Diary (CCD) Score at Week 24
Tidsramme: Baseline, Week 24
|
The CCD is a participant-completed daily diary used to assess chronic cough. The CCD score ranges from 0 to 16, with a higher score indicating worse symptoms. |
Baseline, Week 24
|
|
Percentage of Participants with CCD Response at Week 24
Tidsramme: Week 24
|
Percentage of participants with CCD response will be summarized. |
Week 24
|
Samarbejdspartnere og efterforskere
Efterforskere
- Studieleder: GSK Clinical Trials, GlaxoSmithKline
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 221851
- BUS-P3-02 (Anden identifikator: Bellus Health Inc)
- 2024-513462-19-00 (Anden identifikator: EU CT Number)
- BUS-P3-02 (Anden identifikator: Company)
- 2022-000188-38 (Registry Identifier: EudraCT (EU))
- 2024-513462-19-00 (Registry Identifier: CTIS (EU))
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .